US FDA advisors back AstraZeneca's Crestor for CV disease prevention
16 December 2009
Sue Sutter
Please Login to read the full article.
16 December 2009
Sue Sutter
The US FDA's outside experts have overwhelmingly endorsed the use of AstraZeneca's Crestor (rosuvastatin) for primary prevention of cardiovascular disease based on the results of the JUPITER trial, clearing the way for a significant broadening of the statin's indication.
In a...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US Capitol Capsule: Use of mind-altering medicines in children, elderly under fire
- FDA panel backs Merck's Vytorin in predialysis CKD, but rejects dialysis use
- Pfizer may try to take Lipitor OTC, but history is against it
- Close but no cigar for Crestor in head-to-head Lipitor study
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
